The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.

The FDA approved depemokimab as an add-on maintenance treatment in patients aged at least 12 years with severe asthma and an ...

GSK plc GSK announced that the FDA has approved Exdensur (depemokimab-ulaa), an ultra-long-acting IL-5–targeting biologic, as ...

If the FeNO level is not raised, it is recommended that the patient be offered either a Long-Acting Muscarinic Antagonist ...

Indiana University School of Medicine researchers are taking a closer look at how young patients respond to biologic ...

This new data was the result of a recent case-controlled study that aimed to assess the effects of a PDL that provides an exemption from out-of-pocket cost sharing for patients’ asthma medications on ...

Please provide your email address to receive an email when new articles are posted on . In 2011, 23.2% of adults with asthma experienced cost-related medication nonadherence vs. 13.1% in 2022. The ...

Despite a declining trend, the number of adults in the U.S. who say they did not adhere to their asthma treatment because of costs remains high, according to an observational study. From 2011-2022, ...

Are you one of those families racing to find new asthma medications as respiratory virus season approaches? The Massachusetts Department of Public Health is trying to help patients and families access ...

In 2017, an expert commission organized by the Lancet examined the current state of asthma care. That commission identified poor medication adherence as one of the principal barriers standing between ...

Study results show that patients with chronic obstructive pulmonary disease (COPD) and comorbid asthma may have a greater risk of hospitalization from COVID-19 if they use bronchodilators or steroids ...

(NewsNation) — A Wisconsin family is suing Walgreens and insurance companies after they say the rising costs of asthma medication led to the death of their 22-year-old son last year. Cole ...